Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
2.828 CHF +9.95% Intraday chart for Idorsia Ltd +32.89% +33.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Idorsia's Chief Medical Officer to Step Down at March-end; Successor Named MT
Transcript : Idorsia Ltd - Special Call
US FDA OKs Idorsia's Hypertension Treatment in Combination with Other Antihypertensive Drugs MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod MT
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod MT
Sosei Group Changes Names of Company, Subsidiaries MT
US Futures Slightly Down, European Stocks Edge Up DJ
Transcript : Idorsia Ltd Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
US Futures Mixed, European Stocks Mostly Down DJ
Switzerland's Idorsia Seeks Additional Funding to Extend Cash Runway in FY24 MT
US Futures, European Stocks Climb DJ
US Futures Climb, European Stocks Slip DJ
Sosei Group to Market PIVLAZ Drug in South Korea from 2025 MT
US Futures, European Stocks Edge Up DJ
US Futures, European Stocks Fall as Investors Await Fresh Cues DJ
US Futures, European Stocks Rise DJ
Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023 CI
US Futures, European Stocks Rise DJ
Idorsia Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Transcript : Idorsia Ltd, Nine Months 2023 Earnings Call, Oct 24, 2023
Idorsia Returns to Profitability in Q3 as Net Revenues Expand MT
Idorsia Ltd Updates Earnings Guidance for the Year 2023 CI
US Futures, European Stocks Down as Markets Await BOE Decision DJ
Global markets live: Apple, Alphabet, Roku, Amazon, General Mills... Our Logo
Idorsia to Buy Back Hypertension Drug Rights from Janssen Biotech in Up to CHF306 Million Deal MT
Chart Idorsia Ltd
More charts
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.828 CHF
Average target price
2.099 CHF
Spread / Average Target
-25.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Idorsia Ltd - Swiss Exchange
  4. News Idorsia Ltd
  5. Switzerland's Idorsia Wins Japanese Nod For Hemorrhage Drug